Ipca Laboratories Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0f4qprvblwm3ga6eb8blf7ss.pdf

Key Takeaways


Stand-alone Margin Drivers & Input Cost Pressure

A.K. Jain: "As far as the domestic market is concerned, products which are in price control, the prices remain at the same level. You can't increase even a paisa on that."

Unichem: The Consolidation Overhang

A.K. Jain: "We foresee that I think Unichem margin may become around 12% to 13% in the current financial year from that level. And from that level, again in future years as our filings in other markets start coming up and then we start launching products in other markets. Margins will keep on improving."

Domestic Formulation: The Steady Compounders

A.K. Jain: "More number of products you launch, the attention of the people get diluted and that results in the overall defocus from the main power brands."

Export Formulation & API


Subsidiaries & Associates: Mixed Bag


Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growth~12%–13%FY27
Consolidated EBITDA marginImprove from 20.7% to ~22% or 22.3%FY27
Stand-alone EBITDA marginImprove by ~1%–1.25% (lowered from ~1.5%+ due to material cost)FY27
Unichem EBITDA marginRecover to 12%–13%FY27
Unichem U.S. revenue growth~10%FY27
Unichem product launchesAt least 5–6 productsFY27
Domestic formulation growth~12% (1%–2% from new products, balance price and volume)FY27
U.S. generics commercialization6–8 productsFY27
Overall material cost increase~10%–12%, with ~0.5%–0.75% impact on material cost ratioFY27 (conditional on petroleum prices holding)
Decontrolled product price increase~6%–7%FY27
Pisgah Labs formulation facilityCommissioningQ4 FY27
Pisgah Labs meaningful turnoverRevenue contribution beginsFY28

Key Metrics

MetricQ4 FY26
Consolidated revenue₹2,388 cr, +6% YoY
Consolidated revenue (FY26)₹9,646 cr, +8% YoY
Stand-alone EBITDA margin25.27%, vs 21.19% in Q4 FY25, improvement of ~4.08 ppt
Stand-alone EBITDA margin (FY26)25.18%, vs 22.66% in FY25, improvement of ~2.52 ppt
Consolidated EBITDA margin20.52%, vs 18.24% in Q4 FY25, improvement of ~2.28 ppt
Consolidated EBITDA margin (FY26)20.72%, vs 19.94% in FY25, improvement of ~1.78 ppt
Domestic formulation revenue₹853 cr, +12% YoY
Domestic formulation revenue (FY26)₹3,817 cr, +10% YoY
Export formulation revenue (FY26)₹2,083 cr, +9% YoY
Promotional branded export revenue (FY26)₹664 cr, +14% YoY
Generic business revenue, ex-tenders (FY26)₹1,149 cr, +17% YoY
Institutional business revenue₹74 cr, -33% YoY
API business revenue (FY26)₹1,396 cr, +10% YoY
Consolidated U.S. business revenue₹428 cr, +10% YoY
Consolidated U.S. business revenue (FY26)₹1,567 cr, +14% YoY
Unichem EBITDA margin (FY26)~8%, declined from 12% in FY25
Domestic market share (MAT March '26)2.09%, vs 2.08% in MAT December '25
Freight cost increase~25% QoQ
Material cost to sales ratio (stand-alone)25%
Unichem R&D spend (FY26)3.71% of sales
Unichem Ireland overhead cost savings (FY27)EUR 4 mn–EUR 5 mn per year, expenditure stopping
FY27 consolidated revenue growth guidance12%–13%
FY27 consolidated EBITDA margin guidance~22%–22.3%
FY27 Unichem EBITDA margin guidance12%–13%
FY27 domestic branded growth guidance~12%, with 1%–2% from new products